Assessing Myocardium at Risk: Applying SYNTAX

Similar documents
EXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017

Left Main Disease: what is left to surgery? Prof. Jacques Monségu CardioVascular Institute Grenoble, France

Left Main Intervention: Where are we in 2015?

Left Main Intervention: Will it become standard of care?

PCI for Left Main Coronary Artery Stenosis. Jean Fajadet Clinique Pasteur, Toulouse, France

Mise à Jour sur le traitement du Pluritronculaire Philippe Généreux, MD

PCI for LMCA lesions A Review of latest guidelines and relevant evidence

Three-Year Clinical Outcomes with Everolimus-Eluting Bioresorbable Scaffolds: Results from the Randomized ABSORB III Trial Stephen G.

PCI vs. CABG From BARI to Syntax, Is The Game Over?

TLR des Stents Actifs

Left Main PCI vs. CABG: Real World

ΑΓΓΕΙΟΠΛΑΣΤΙΚΗ ΣΤΟ ΔΙΑΒΗΤΙΚΟ ΑΣΘΕΝΗ

Resolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program

Le# Main Interven-on: When Is It Appropriate. Femi Philip, MD Assistant Professor Of Medicine UC Davis

VCU Pauley Heart Center: A 2009 US News Top 50 Heart and Heart Surgery Hospital

PTCA 1979: : I

Lésions du tronc commun: Reste t il une place pour la chirugie? Pierre Deharo, CHU TIMONE, Marseille

New Generation Drug- Eluting Stent in Korea

Drug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis Alaide Chieffo

Abbott Vascular. PROTOCOL EXCEL Clinical Trial

Controversies in Coronary Revascularization. Atlanta CCU April 15, 2016

7-Year Follow-up From a Randomized Trial of Sirolimus-Eluting vs. Everolimus-Eluting Stents in Patients With Coronary Artery Disease (RESET)

COMPARE Trial Elvin Kedhi Maasstad Ziekenhuis Rotterdam The Netherlands

LEFT MAIN PERCUTANEOUS CORONARY INTERVENTION. A/Prof Koh Tian Hai Medical Director National Heart Centre, Singapore

Important LM bifurcation studies update

Surgical vs. Percutaneous Revascularization in Patients with Diabetes and Acute Coronary Syndrome

ISAR-LEFT MAIN 2 Randomized Trial. Zotarolimus- vs. Everolimus-Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions

Benefit of Performing PCI Based on FFR

Management of High-Risk Coronary Artery Disease

Perspective of LM stenting with Current registry and Randomized Clinical Data

Unprotected Left Main Stenting: Patient Selection and Recent Experience. Alaide Chieffo. S. Raffaele Hospital, Milan, Italy

Surgery Grand Rounds

Can Angiographic Complete Revascularization Improve Outcomes for Patients with Decreased LV Function? NO!

Komplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents

Diabetic Patients: Current Evidence of Revascularization

Controversies in Cardiac Surgery

Δημήτριος Αγγοσράς, FETCS

Michael Mack, M.D. Baylor Healthcare System Heart Hospital Baylor Plano Dallas, TX

HREVS: A Randomized Trial of PCI vs CABG vs Hybrid Revascularization in Patients With Coronary Artery Disease. Vladimir Ganyukov, MD, PhD

TNT Session. The latest clinical evidence in diabetics for the Amphilimus TM eluting polymer-free DES. Rafael Romaguera, MD

Clinical Considerations for CTO

Coronary stenting: the appropriate use of FFR

Mid-term results from real-world REPARA registry. Felipe Hernandez, on behalf of the REPARA investigators

Ultimaster clinical results in left main and bifurcations

Reconciling the Results of the Randomized Trials

Implications of the New ESC/EACTS Guidelines for Myocardial Revascularization in 2011

Coronary Stent Choice in Patients With Diabetes Mellitus

Rationale for Percutaneous Revascularization ESC 2011

Management of cardiovascular disease - coronary interventions -

When should we indisputably perform CABG? Quand faut-il indiscutablement opérer? Dr Hakim BENAMER

CABG vs PCI: What do the Guidelines Say?

high SYNTAX Score? I Sheiban Division of Cardiology Interventional Card. University of Turin Turin / Italy

What s New in Antiplatelet Therapy and DES in 2016

Michael Mack, M.D. Baylor Healthcare System Heart Hospital Baylor Plano Dallas, TX

SAHA PCI or CABG for Left Main and Multi-Vessel Disease: when I would definitely/ maybe/never refer my patient for PCI or CABG

Most Patients with Elective Left Main Disease. Farrel Hellig

Advances in Cardiovascular Diagnosis and Therapy. No disclosure or conflicts. Outline

Fractional Flow Reserve: Basics, FAME 1, FAME 2. William F. Fearon, MD Associate Professor Stanford University Medical Center

SYNTAX score before decision making! Corrado Tamburino, MD, PhD

Southern Thoracic Surgical Association CABG in 2012: Implications of the New ESC/EACTS Guidelines

Medical Rx vs PCI vs CABG

COMMENT DEFINIR UN PLURITRONCULAIRE. Didier Carrié CHU Toulouse Rangueil

Unprotected LM intervention

Left Main and Bifurcation Summit I. Lessons from European LM Studies

Count Down to COMBAT

Chronic Total Occlusions Rajan Patel, MD FACC FAHA FSCAI

Clinical Seminar. Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective

Utilities and Pitfalls of Composite and Surrogate Endpoints in Clinical Trials. Cardiovascular Research Foundation Columbia University Medical Center

Coronary Artery Disease: Revascularization (Teacher s Guide)

The SYNTAX-LE MANS Study

Hyeon-Cheol Gwon, On the behalf of SMART-DATE trial investigators ACC LBCT 2018

Ziyad Ghazzal MD, FACC, FSCAI Professor of Medicine Deputy Vice President/Dean Associate Dean for Clinical Affairs American University of Beirut

Disclosures. Theodore A. Bass MD, FSCAI. The following relationships exist related to this presentation. None

LM stenting - Cypher

Quality of Life After Everolimus- Eluting Stents or Bypass Surgery for Treatment of Left Main Coronary Artery Disease:

Left Main PCI. Integrated Use of IVUS and FFR. Seung-Jung Park, MD, PhD

Final Clinical and Angiographic Results From a Nationwide Registry of FIREBIRD Sirolimus- Eluting Stent: Firebird In China (FIC) Registry (PI R. Gao)

Pieter Stella, MD, PhD

Management of Stable Ischemic Heart Disease. Vinay Madan MD February 10, 2018

Absorbable Scaffolds the Future of Coronary Interventions?

Background. Drug-eluting stents (DES) are increasingly used in complex patients with a high clinical or lesion-related risk of adverse events.

Cindy L. Grines MD FACC FSCAI

ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions

What do the guidelines say?

Stephen G. Ellis, M.D. Professor of Medicine Director Invasive Services Co-Director Cardiac Gene Bank

eucalimus - First Experience

Drug Eluting Stents: Bifurcation and Left Main Approach

R&M Solutions

FFR-Guided PCI. 4 th Imaging and Physiology Summit October 29 th, 2010 Seoul, Korea. Stanford

DES in Diabetic Patients

PCI for Stable Ischemic Heart Disease: What Happened in the Last Week?

HCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February Drug-eluting stents Are they all equal?

Current Status of BioresorbableScaffolds: Moving Forward or Backwards?

The Case for PCI as the Preferred Therapy in Most Patients with Chronic Stable Angina

SKG Congress, 2015 EVOLVE II. Stephan Windecker

Application of Appropriate Use Criteria in Clinical Care of CAD. Peter K. Smith, MD Professor and Chief Thoracic Surgery Duke University 4/29/2012

Clinical Considerations for CTO Revascularization

Complicated PTCA of Left Main Total Occlusion in NSTEMI

EXAMINATION trial. Manel Sabaté Hospital Clínic, Barcelona (On behalf of the Examination Investigators)

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors

Transcription:

Assessing Myocardium at Risk: Applying SYNTAX Farouc Jaffer MD PhD FSCAI FACC FAHA Associate Professor of Medicine, Harvard Medical School Director, CAD Program and Chronic Total Occlusion PCI Program Cardiology Division, Massachusetts General Hospital Session: PCI: Left Main and Multi-Vessel SCAI 2015 Fall Fellows Course, Las Vegas 2015 Dec 7 8:54AM

Disclosure Slide Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below. Affiliation/Financial Relationship Research Grant Consultant Intellectual Property (held by MGH) Company Kowa, Siemens, Canon Boston Scientific, Abbott Vascular Canon June 2015

CABG or PCI for Complex CAD?

Clinical case of Unprotected Left Main CAD 64F HTN, asthma, COPD presents with UAP. EW briefly hypotensive to 70s. ECG with ST depressions during angina. TnT negative Cath: RCA ok. 80% ostial left main with catheter damping. Mild LAD and CFX CAD. L SCL occluded. Nondiabetic. EF normal 67%. FEV1 reduced 0.85L CABG or PCI?

Overall results of the SYNTAX trial for PCI vs. CABG for Three Vessel CAD (3VD) or Left Main (LM) Landmark RCT 1 that demonstrated the value of (1) anatomical Syntax Score and (2) A CAD Heart Team approach to guide decision making between PCI and CABG Real-world 1800 pt trial; 41% of screened patients enrolled Primary endpoint: Non-inferiority of PES PCI and CABG at 1 year was not met, due to increased revascularization in PCI. Five year outcomes 2 based on Syntax Score (SS): CABG showed significantly reduced MACCE in: 3VD: Intermediate (23-32) and High (33+) SS groups Left main (LM): High (33+) Syntax score group 1 Serruys et al. New England Journal of Medicine 2009; 360:961-972 2 Mohr et al. Lancet 2013;381:629-638 (SYNTAX Five year follow-up)

Analyzing the Benefit of CABG vs. PCI in Syntax * 5 year MACCE for combined 3VD and LM * Low SS (0-22): MACCE n.s.: Subgroup TVR p=0.056. Intermediate SS (23-32): MACCE: MI, revasc * High SS (33+): MACCE: All-cause death, Cardiac death, MI and revasc Stroke neutral at 5 years Mohr et al. Lancet 2013;381:629-638

Limitations of the SYNTAX Trial (2005-2009) PCI Approach: We are so much better in 2015! New generation DES: MI, Revasc Better DAPT: ticagrelor and prasugrel to stent thrombosis / MI / revasc / death. Less incomplete revasc (linked to MACCE): CTO PCI CABG Approach: Applicable to the US? 28% Bilateral IMAs, 19% all arterial revascularization SYNTAX Score: Does not incorporate clinical characteristics Moderate interobserver variability New scores may improve the predictive accuracy the SS: SYNTAX II (Farooq et al. Lancet 2013) Functional SS (FFR-guided; invasive and noninvasive CT)

1st generation DES 2nd/3rd generation DES 1st generation DES Sirolimus eluting stent (SES) Paclitaxel eluting stent (PES; used in SYNTAX) 2nd/3rd generation DES CoCr Everolimus eluting stent (EES), PtCR EES Phosphylcholine Zotarolimus ES, Resolute ZES; PtCR PES

SPIRIT IV EES vs. PES: EES: Revascularization, Stent thrombosis at 1 year -GW Stone, et et al. SPIRIT IV 1 year NEJM EES CV Death /MI 30% CV death/mi TLF PES EES PES EES Ischemia-TVR ST PES PES EES EES EES TVR 50% EES ST 70%

EES: stent thrombosis by 2/3 rds compared to PES Palmerini et al. Methods: Network meta-analysis of RCTs of DES and BMS Findings: 49 trials, N=50 844 patients from RCTs. CoCr-EES vs. PES: CoCr-EES vs. PES: 1-year definite ST (OR 0.28, p<0.05) 2-year definite ST (OR 0.34, p<0.05) Interpretation: CoCr-EES substantially lowers ST compared to PES

Benefits of EES may not be extendable to patients with diabetes, however 2011;124:893-90 Methods: Pooled SPIRIT II, III, IV, COMPARE trials: CoCr-EES v. PES Findings: N=6780 patients. N=1869 (28%) with diabetes. No Diabetes: Significant reductions in 2 year death ( 39%), MI ( 50%), ST ( 88%), and ischemia-tvr ( 50%) Diabetes: No significant differences in 2 year outcomes Interpretation: CoCr-EES performs similarly to PES in diabetics

New off the press: EES is superior to PES in diabetics Taxus Element vs. Xience Prime, NEJM October 15, 2015

Modeling SYNTAX 5 year outcomes in Nondiabetics Using EES instead of PES EES vs. 1st gen PES, No Diabetes: TLR 50%, MI 50% Intermediate SS (23-32) High SS (33+) PES EES predicted PES EES predicted * p=ns? * p=ns? PES EES predicted PES EES predicted * p=ns? * p=ns?

The latest randomized trials suggests CABG still superior to EES for MVD..but some limits 1776 pts planned. 27 centers. Asia. RCT EES vs CABG -- SJ Park et al. NEJM 2015 March. BEST trial D+MI+TVR 2 yrs Stopped for slow enrollment N =886. 20% of those screened w ere enrolled. Mean SS 24. Limitations: (1) 40% diabetic! Subgroup of non diabetics was similar for primary endpoint; (2) CR PCI rate ½ that of CABG. Favors CABG

ESC 2014 Guidelines: More Support for Appropriate PCI in Complex CAD, including Left Main Left main and low SYNTAX score: PCI and CABG are BOTH Class I

Rationale for a CAD Heart Team Decision making for patients with multivessel or left main CAD is improved by collaboration between cardiac surgeons, interventional cardiologists, referring cardiologists, and other specialists A CAD Heart Team is a Class I recommendation (AHA, ESC) Initiated at MGH Fall 2014. CAD Heart Form filled out ahead of time including STS and Syntax scores (see next slide). Weekly meeting available for outpatient discussion, ad hoc meetings within 24 hours for inpatients.

CAD Heart Team Form Part 1

CAD Heart Team Form Part 2

Conclusions Major advances in PCI (new DES, better DAPT, CTO PCI) have occurred since publication of SYNTAX: Stent thrombosis, MI, Revascularization, rss leading to improved PCI outcomes compared to SYNTAX era Currently, it may be reasonable to practice as follows: In non-diabetic individuals who are EES candidates: Low SYNTAX Score: Intermediate SYNTAX Score: High SYNTAX Score: PCI or CABG reasonable CABG or PCI reasonable CABG preferred In all cases, CABG-PCI decisions should be individualized based on a CAD Heart Team evaluation and patient-centered decision making

Clinical Case Follow-Up CAD Heart Team Meeting: STS 1.6% mortality, low-risk. Surgeon however concerned about lung disease and prolonged ventilation Syntax Score 16. Syntax II favored PCI (43 vs. 47 points for CABG). AHA 2011 Guidelines: PCI: Class IIa (B) CABG: Class I (B) ESC 2014 Guidelines: PCI: Class I (B) CABG: Class I (B) Heart Team recommended UPLM PCI. Patient underwent successful LM PCI with a two DES in Culotte orientation, IVUS guided, no support (performed by our own Doug Drachman!)

Thank you for your attention!